Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in advanced urothelial transitional cell carcinoma
NCT00578526Phase 2Completed
- Sponsor
- American Health Staffing Group
- Start
- Apr 2008
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in urothelial carcinoma (UC) comparing Sunitinib with Placebo (2 arms). Primary endpoint: Progression-Free Survival at 4 months. Started Apr 2008; status: completed.
02
Drugs
sunitinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00578526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00578526.